0001209191-22-022692.txt : 20220404
0001209191-22-022692.hdr.sgml : 20220404
20220404192504
ACCESSION NUMBER: 0001209191-22-022692
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220404
FILED AS OF DATE: 20220404
DATE AS OF CHANGE: 20220404
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Thomson Mary Christina
CENTRAL INDEX KEY: 0001295674
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37490
FILM NUMBER: 22804670
MAIL ADDRESS:
STREET 1: C/O SIERRA ONCOLOGY, INC.
STREET 2: 1820 GATEWAY DRIVE, SUITE 110
CITY: SAN MATEO
STATE: CA
ZIP: 94404
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sierra Oncology, Inc.
CENTRAL INDEX KEY: 0001290149
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1820 GATEWAY DRIVE
STREET 2: SUITE 110
CITY: SAN MATEO
STATE: CA
ZIP: 94404
BUSINESS PHONE: (605) 376-8679
MAIL ADDRESS:
STREET 1: 1820 GATEWAY DRIVE
STREET 2: SUITE 110
CITY: SAN MATEO
STATE: CA
ZIP: 94404
FORMER COMPANY:
FORMER CONFORMED NAME: ProNAi Therapeutics Inc
DATE OF NAME CHANGE: 20040513
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-04-04
0
0001290149
Sierra Oncology, Inc.
SRRA
0001295674
Thomson Mary Christina
C/O SIERRA ONCOLOGY, INC.
1820 GATEWAY DRIVE, SUITE 110
SAN MATEO
CA
94404
0
1
0
0
General Counsel, CCO & Sec'y
Common Stock
2022-04-04
4
M
0
2000
13.04
A
2000
D
Common Stock
2022-04-04
4
S
0
2000
35.1384
D
0
D
Stock Option (Right to Buy)
13.04
2022-04-04
4
M
0
2000
0.00
A
2030-07-28
Common Stock
2000
0
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020. The Reporting Person is subject to a Lock-Up Letter Agreement that expires on April 26, 2022. The sale of shares is a permissible exemption under the terms of the Lock-Up Letter Agreement.
On July 28, 2021, the option vested as to 25% of the total shares granted on July 28, 2020, with the remaining shares from that grant vesting in equal monthly installments over the following 36 months, with 100% of the total shares vested on July 28, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
/s/ Mary Christina Thomson
2022-04-04